Aliment Pharmacol Ther

1. POLLOK R
   Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis.
   Aliment Pharmacol Ther. 2025 Sep 30. doi: 10.1111/apt.70368.
   

   >> Share

   
   
2. MATHIAS RM, Bogatic D, Bryant RV
   Editorial: Is Disease Clearance the Target in Ulcerative Colitis or a Stride Too Far?
   Aliment Pharmacol Ther. 2025 Sep 26. doi: 10.1111/apt.70291.
   

   >> Share

   
   

   
   Am J Gastroenterol

3. SANDS BE, Rubin DT, Loftus EV Jr, Wolf DC, et al
   Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
   Am J Gastroenterol. 2025;120:2339-2349.
   

   >> Share

   
   
4. PARK Y MD, Park JH DDS, Leem GH, Song TJ MD, et al
   Periodontitis and the Incidence of Inflammatory Bowel Diseases: A Nationwide Population-Based Cohort Study.
   Am J Gastroenterol. 2025;120:2361-2372.
   

   >> Share

   
   
5. HUAN PW, Mehta A, Wong ECL, Dulai PS, et al
   A Review of the Modified Multiplier of Simple Endoscopic Score for Crohn's Disease and How to Use It in Clinical Trials and Practice.
   Am J Gastroenterol. 2025;120:2242-2250.
   

   >> Share

   
   
6. PAL P, Mateen MA, Pooja K, Marri UK, et al
   Correlation and assessment of small bowel lesions using cross sectional imaging techniques compared to small intestinal contrast ultrasonography in known Crohn's disease (the CACTUS-CD study): a paired, prospective, confirmatory study.
   Am J Gastroenterol. 2025 Sep 29. doi: 10.14309/ajg.0000000000003776.
   

   >> Share

   
   
7. RD L, Tc J, F Z, Y H, et al
   Gut microbiota are more strongly associated with impairments in health-related quality of life than disease activity in inflammatory bowel disease.
   Am J Gastroenterol. 2025 Sep 29. doi: 10.14309/ajg.0000000000003773.
   

   >> Share

   
   
8. KOCHAR B, Katz S, Faye AS
   Practical Advice for the Management of Older Adults With Inflammatory Bowel Disease.
   Am J Gastroenterol. 2025;120.
   

   >> Share

   
   

   
   BMC Gastroenterol

9. IGBO CA, Ezeano C, Adeniran O, Taha M, et al
   The impact of fecal microbiota transplantation on refractory ulcerative colitis: A systematic review and Meta-Analysis of randomised controlled trials.
   BMC Gastroenterol. 2025;25:654.
   

   >> Share

   
   
10. YE K, Zhou T, Jin Z, Jiang W, et al
    A study of the protective association of hard water on ulcerative colitis and Crohn's disease: a cross-sectional and cohort study of 481,468 participants in the UK Biobank.
    BMC Gastroenterol. 2025;25:666.
    

    >> Share

    
    
11. LIU J, Zhang D, Wang Y, Zhang Y, et al
    Relationship between serum total bilirubin levels and primary loss of response to Infliximab therapy in Crohn's disease patients.
    BMC Gastroenterol. 2025;25:683.
    

    >> Share

    
    
12. TAN L, Li Y, Ding C, Qian J, et al
    Serum biomarkers of intestinal barrier dysfunction predict postoperative endoscopic recurrence in Crohn's disease patients.
    BMC Gastroenterol. 2025;25:668.
    

    >> Share

    
    
13. XIANG X, Hu Z, Dong S, Qi B, et al
    Therapeutic regimen of Crohn's disease: effect of Infliximab combined with mesalazine on intestinal flora and inflammatory indexes in patients.
    BMC Gastroenterol. 2025;25:687.
    

    >> Share

    
    
14. LI L, Xu X, Wang J, Xie L, et al
    Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn's disease who develop secondary loss of response to infliximab.
    BMC Gastroenterol. 2025;25:685.
    

    >> Share

    
    

    
    Clin Gastroenterol Hepatol

15. BEN HUR D, Issaschar G, Moshe R, Lebedenko B, et al
    Risk of Age-related and Disease-related Complications and Mortality in Elderly-onset Inflammatory Bowel Disease: A Population-based Study.
    Clin Gastroenterol Hepatol. 2025;23:1982-1990.
    

    >> Share

    
    
16. REZAZADEH ARDABILI A, Le Berre C, Colombel JF
    Advanced therapies in Crohn's disease: a critical appraisal of location-based efficacy.
    Clin Gastroenterol Hepatol. 2025 Sep 22:S1542-3565(25)00839.
    

    >> Share

    
    
17. UEKADO H, Watanabe D, Kodama Y
    Syphilitic Proctitis Mimicking Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2025 Sep 29:S1542-3565(25)00849.
    

    >> Share

    
    

    
    Clin Res Hepatol Gastroenterol

18. YZET C, Robert C, Brazier F, Meudjo E, et al
    Impact of histological healing on ulcerative colitis disease course among patients with endoscopic healing: results of a prospective study.
    Clin Res Hepatol Gastroenterol. 2025;49:102700.
    

    >> Share

    
    
19. BERTRAND A, Meyer A, Kirchgesner J, Uzzan M, et al
    Effectiveness and safety of third-line advanced therapies in patients with ulcerative colitis: A multicentre retrospective cohort study: Third-line treatment in UC.
    Clin Res Hepatol Gastroenterol. 2025 Sep 29:102699.
    

    >> Share

    
    

    
    Gastroenterol Hepatol

20. JIANG P, Li Y, Tian J, Luo Y, et al
    Efficacy and safety of biologic therapy for Crohn's disease: An overview of meta-analyses and systematic reviews.
    Gastroenterol Hepatol. 2025;48:502432.
    

    >> Share

    
    

    
    Gut

21. 
    Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025 Sep 26:gutjnl-2024-334395corr1. doi: 10.1136/gutjnl-2024-334395.
    

    >> Share

    
    

    
    Inflamm Bowel Dis

22. HANNA LN, Quraishi B, Pelly T, Lung P, et al
    Therapeutic Benefit of Upadacitinib in Severe Post-Proctectomy (Class 4) Perianal Crohn's Disease: A Three-Patient Case Series.
    Inflamm Bowel Dis. 2025 Sep 24:izaf216. doi: 10.1093.
    

    >> Share

    
    
23. LIN YF, Truchon A, Djoukam Mbuko B, Dai HYL, et al
    Factors Associated with Fistulizing Crohn's Disease in Children at Diagnosis: A Cross-Sectional Study.
    Inflamm Bowel Dis. 2025 Sep 24:izaf220. doi: 10.1093.
    

    >> Share

    
    
24. MCKEIGUE PM, Iakovliev A, Erabadda B, Colhoun HM, et al
    Genome-Wide Aggregated Trans-Effects Analysis Implicates Deficient Type III Interferon Signaling as a Key Cause of Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Sep 25:izaf214. doi: 10.1093.
    

    >> Share

    
    
25. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 25:izaf199. doi: 10.1093.
    

    >> Share

    
    
26. SALWEN-DEREMER JK, Westvold SJ, Aschbrenner K, Smith MT, et al
    Cognitive Behavioral Therapy for Insomnia May Improve Sleep and Pain in Crohn's Disease: A Waitlist Control Pilot Trial.
    Inflamm Bowel Dis. 2025 Sep 25:izaf210. doi: 10.1093.
    

    >> Share

    
    
27. YARUR A, Irving P, Siegmund B, Dubinsky MC, et al
    Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.
    Inflamm Bowel Dis. 2025 Sep 26:izaf195. doi: 10.1093.
    

    >> Share

    
    
28. KANG B, Moon JS, Choi S, Oh SH, et al
    Perianal Disease Modifiers Are Associated With Less Severe Luminal Disease Activity in Children With Crohn's Disease at Diagnosis.
    Inflamm Bowel Dis. 2025 Sep 30:izaf209. doi: 10.1093.
    

    >> Share

    
    
29. BACHOUR SP, Srinivas-Rao S, Baskaran NU, Agrawal M, et al
    Cross-Sectional Imaging Features Associated With Disease Progression in Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 30:izaf219. doi: 10.1093.
    

    >> Share

    
    
30. KALE T, Yoo L, Kroeger E, Iqbal A, et al
    Menopause and Inflammatory Bowel Disease: A Systematic Review.
    Inflamm Bowel Dis. 2025 Oct 1:izaf204. doi: 10.1093.
    

    >> Share

    
    

    
    J Crohns Colitis

31. 
    Correction to: Novel outcomes in inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf117.
    

    >> Share

    
    
32. NIKOLAKIS D, Li Yim AYF, Overberg KL, Ghiboub M, et al
    Drug repurposing approach for the discovery of therapeutic agents for Crohn's disease-associated intestinal fibrosis.
    J Crohns Colitis. 2025;19:jjaf137.
    

    >> Share

    
    
33. WANG Z, Ferrante M, Vermeire S, Dreesen E, et al
    Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study.
    J Crohns Colitis. 2025;19:jjaf151.
    

    >> Share

    
    

    
    J Gastroenterol

34. SONG H, Zhou Y, Liu S, Zhang Q, et al
    Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome: the cross-sectional and longitudinal relationship.
    J Gastroenterol. 2025 Sep 28. doi: 10.1007/s00535-025-02304.
    

    >> Share

    
    

    
    Lancet Gastroenterol Hepatol

35. WU K, Zheng C, Cao Q, Ding Y, et al
    Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
    Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198.
    

    >> Share

    
    

    
    N Engl J Med

36. MULLER F, Atreya R, Volkl S, Aigner M, et al
    CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis.
    N Engl J Med. 2025;393:1239-1241.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share